Evaluation Of Antidiabetic Drug ?- Escin Extracted From Aesculus Hippocastanum In Context Of Respiratory Disease

1. Clinical Context: Diabetes and Respiratory Disease Comorbidity

Due to its increasing incidence and significant impact on public health, type 2 diabetes mellitus (T2DM) has become a worldwide health issue that is expanding quickly. An increasing number of studies indicate that it increases the risk of respiratory issues such as asthma, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD), as well as cardiovascular and kidney disorders (1, 2). Persistent hyperglycemia impairs immune systems and exacerbates oxidative stress and systemic inflammation, all of which increase the risk of pulmonary problems (3).

2. Pathophysiological Interplay: Immune Dysregulation and Oxidative Stress

Nuclear factor kappa B, or NF-kappa B, is activated by elevated blood sugar levels. This leads to increased production of many chemicals, including interleukin-6, interleukin-1 beta, and tumour necrosis factor-alpha. These factors contribute to inflammation of the lungs. The body produces an excessive amount of harmful chemicals known as reactive oxygen species during this time. Additionally, the body contains beneficial substances like superoxide dismutase that support our health (4,5). The lung tissues are harmed as a result.
People with diabetic respiratory disorders suffer greatly from the combination of blood sugar levels, lung inflammation, and oxidative stress. Therefore, medical professionals believe that managing oxidative stress and inflammation is crucial to improving the symptoms of respiratory disorders.

3. β -Escin from Aesculus hippocastanum: Therapeutic Profile

3.1 Traditional Use and Pharmacology

β-Escin is a substance found in horse chestnut seeds. People can benefit from this type of combo. It is used to treat inflammation and veins. It is used to treat haemorrhoids and leg oedema. Venous insufficiency can also be treated with horse chestnut seeds' β-Escin. (6,7)
It works by strengthening the small blood arteries and improving vein function. This is due to the fact that horse chestnut seeds contain β-Escin, which can improve vein function and reduce blood vessel leakage. (8)

3.2 Molecular Mechanisms and Safety Profile

One feature of β-escin is its multifunctionality. It supports cytoskeletal remodelling and the synthesis of cholesterol. Additionally, it promotes cell adhesion, which is crucial for vascular stability.(9)
β-escin has an effect as well. It lessens inflammatory factors. It inhibits NF-κB, which is crucial for its anti-inflammatory properties. It is crucial to understand that β-escin is safe to use. Studies conducted on humans and animals have demonstrated that β-escin has a low number of adverse effects and a safety profile.(10)

4. Anti-Inflammatory and Antiviral Potential

4.1 Airway Inflammation and Allergy Models

β-escin significantly reduced the quantity of white blood cells that enter the airways in mice with airway inflammation, as well as the body's production of specific molecules including IL-5 and IL-13. This is comparable to the effects of corticosteroids, such as dexamethasone.(11, 12) This suggests that β-escin may be helpful in treating conditions that lead to airway inflammation, such as allergic airway inflammation and other inflammatory respiratory disorders, where β-escin may be crucial.

4.2 Antiviral and Immunomodulatory Effects

The thing about β-escin is that it also has some effects, against viruses. It was seen in some studies that β-escin can stop the syncytial virus from making more of itself and also reduce the inflammation that the virus causes in the cells that line the airways.(13) Some new studies are saying that β-escin might be good to use against SARS-CoV-2 and other coronaviruses because it can stop some things from happening like the activation of NF-κB and the cytokine storm pathways, which are both things that β-escin can suppress (14,15).

5. β-Escin's Antidiabetic and Antioxidant Effects

The thing about β-escin is that it does a lot more than help with inflammation and viruses. β -escin also has an impact on diabetes. When scientists studied β-escin they found out that it helps the body use insulin better and reduces the effects of having too much sugar in the blood for a long time. β -escin is also good for people with diabetes because it helps reduce inflammation and damage to tissues in the kidneys and heart. (16) It does this by controlling things that can cause damage like malondialdehyde, Matrix metalloproteinases and transforming growth factor-β, which are all connected to oxidative stress. So β-escin is really helpful in dealing with the problems that come with diabetes, like kidney and heart disease(17,18).

6. Research Gap and Study Rationale

The thing about β-escin is that it appears to aid with diabetes, infections, and inflammation. Surprisingly, no significant research has been done to determine whether β-escin can help those with diabetes who also have respiratory issues. Since both diabetes and breathing issues entail issues like stress on the body, inflammation, and malfunctioning metabolism, β-escin appears to be quite beneficial. Therefore, β-escin may be a useful treatment for these problems.

7. Objective of the Study

The impact of β-escin on health was investigated in two conditions: acute lung injury, which is exacerbated by lipopolysaccharide, and a kind of diabetes produced by streptozotocin. The researchers believed that β-escin would improve the body's metabolism and lessen oxygen-induced oedema and damage to the lungs.
They sought to determine whether β-escin could perform the following functions:

• Assist in regulating blood sugar levels.
• Minimise lung oedema and oxygen-related damage.
• Modify bodily impulses that lead to inflammation.
• Assist in defending the respiratory system and lungs.

Additionally, β-escin's anti-inflammatory and antioxidant properties in hyperglycaemic circumstances will be evaluated in vitro using bronchial epithelial and macrophage cell lines.

Materials and Methods

1. Chemicals and Reagents

β-Escin (≥98% purity), streptozotocin (STZ), lipopolysaccharide (LPS; E. coli O111:B4), and MTT reagent were supplied by Sigma-Aldrich. The cell culture media and supplements, including DMEM, foetal bovine serum, penicillin-streptomycin, and trypsin-EDTA, were provided by Gibco. Antibodies against NF-κB p65, IL-6, TNF-α, IL-1β, and β-actin were supplied by Cell Signalling Technology.

2. Plant Material and Extraction of β-Escin

We purchased Aesculus hippocastanum seeds from a reliable plant seller verified by a Pharmacognosy Department plant specialist. The department's plant library contained a sample of the seeds (voucher No. AH-2025).To extract chemicals, the seeds were crushed, dried, and combined with 70% ethanol.This blend was. then used a specialised equipment to filter and reduce.Next, a method known as preparative HPLC was used to purify the extract. It was β-escin. Similar to previous investigations on Aesculus hippocastanum seeds and β-escin, their quality was examined using HPLC and LC-MS techniques.Aesculus hippocastanum and β-escin seeds were crucial to the research.The specialists ensured the purity of the β-escin derived from Aesculus hippocastanum seeds.(19,20).

3. Experimental Animals

The institutional animal facility supplied male Sprague-Dawley rats (n = 48; 8 weeks old; 180–220 g) that were acclimated to conventional laboratory settings (22 ± 2 °C, 55% relative humidity, and a 12-hour light/dark cycle). Food and water were provided at no cost during the trial. The experimental techniques, which were conducted in compliance with the Government of India's CCSEA regulations, were authorised by the Institutional Animal Ethics Committee.

4.  Induction of Diabetes Mellitus

To induce diabetes, a single intraperitoneal dose of streptozotocin (55 mg/kg body weight) prepared in 0.1 M cooled citrate buffer (pH 4.5) was administered to rats that had fasted overnight.. At 72 hours and 7 days following STZ treatment, the fasting blood glucose concentrations were measured using an Accu-Chek® glucometer; animals were classified as diabetic and chosen for additional research if their fasting glucose levels were greater than 250 mg/dL.(21).

5. Lung Injury Induction

After the rats were confirmed to be diabetic, they were split at random into six groups of eight rats per group. To generate experimental acute lung injury (ALI) within the rats, lipopolysaccharide (LPS) was administered into the rats’ tracheas at a dose of 5 mg/kg of the rats’ body weight. The LPS was dissolved in 0.9% saline prior to injection. The control rats did not receive LPS and instead only received 0.9% saline (22).

Fig 1: Mechanism of Diabetes-induces Lung Injury

 

Fig 2: Mechanism of β- Escin

 

Fig 3: Integrated Mechanism of β-Escin

 

Fig 4: Potential benefits of Aesculus hippocastanum in respiratory Diseases

 

Fig 5: β-Escin effects on SARS-CoV-2 treatment

 

Fig 6: Experimental study design and procedure

CONCLUSIONS

Based on earlier research designs, our results indicate that β-escin may have important uses in reducing blood glucose levels and LPS-mediated airway inflammation in a diabetic paradigm; however, empirical tests are still required to confirm these findings. Antioxidation, inhibition of NF-κB pathway activation, and a decrease in cytokines and cellular infiltrates are hypothesised to be the mechanisms by which this happens.

REFERENCES

1. Ehrlich SF, Quesenberry CP, Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55–60.
2. Bahloul M, Turki O, Chaari A, et al. Pulmonary complications of diabetic patients admitted in intensive care unit for non-pulmonary disorders. J Diabetes Complications. 2015;29(5):693–7.
3. Jialal I, Devaraj S. Inflammation and oxidative stress in the pathogenesis of atherosclerosis: implications for the therapy of atherosclerosis. Am J Clin Nutr. 2006;84(6):1232–9.
4. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.
5. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50(5):567–75.
6. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012;11:CD003230.
7. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183–93.
8. Belcaro G, Cesarone MR, Dugall M, et al. Escin in the treatment of chronic venous insufficiency. Angiology. 2001;52 Suppl 2:S17–21.
9. Müller-Ladner U, Kriegsmann J, Franklin BN, et al. Influence of β-escin on the cellular cholesterol homeostasis and cytoskeleton of human endothelial cells. Eur J Pharmacol. 2016;791:167–74.
10. Grasing K, Mathur S, Chugh Y, et al. Preclinical safety evaluation of β-escin: A triterpenoid saponin with broad bioactivity. J Ethnopharmacol. 2023;318:117265.
11. Park S, Lee JY, Kim Y, et al. Escin attenuates allergic airway inflammation through the inhibition of NF-κB activation in a murine model of asthma. BMC Immunol. 2010;11:24.
12. Wang H, Zhang N, Cheng J, et al. Effect of β-escin on experimental allergic rhinitis in rats. Int Immunopharmacol. 2018;64:208–14.
13. Zhu X, Liu J, Xu L, et al. Anti-inflammatory effects of β-escin on RSV-induced acute lung injury in mice. Immunopharmacol Immunotoxicol. 2019;41(6):624–31.
14. Pagani I, Bulow L, Hagemeier K, et al. Broad-spectrum antiviral activity of β-escin against SARS-CoV-2 and other respiratory viruses via inhibition of NF-κB. Antiviral Res. 2024;215:105325.
15. Krause J, Bräutigam L, Bentz S, et al. Anti-inflammatory and antiviral activity of Aesculus hippocastanum L. extract against coronavirus. Biomed Pharmacother. 2024;174:114121.
16. Baig MH, Ahmad K, Roy S, et al. In silico and in vivo study of β-escin as an antidiabetic and anti-inflammatory agent. J Mol Struct. 2021;1225:129065.
17. Oueslati S, Karkouch I, Sahnoun Z, et al. Protective effect of Aesculus hippocastanum seed extract in streptozotocin-induced diabetic nephropathy in rats. Biomed Pharmacother. 2016;83:347–54.
18. Turgut NH, Kara H, Elibol E, et al. β-Escin reduces diabetic cardiomyopathy in rats: Role of NF-κB and MCP-1 pathway. J Cell Biochem. 2021;122(2):197–207.
19. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183–93.
20. Grasing K, Mathur S, Chugh Y, et al. Preclinical safety evaluation of β-escin: A triterpenoid saponin with broad bioactivity. J Ethnopharmacol. 2023;318:117265.
21. King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–94.
22. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295(3):L379–99.
23. Hamacher J, Lucas R, Lijnen HR, et al. Tumor necrosis factor-α and acute lung injury. J Investig Med. 2002;50(2):123–35.
24. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421–31.
25. Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.